MarketPulse

Mereo BioPharma

3 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Mereo BioPharma Faces Class Action Over Failed Clinical Trials, Alleged Investor Deception

Mereo BioPharma faces class action lawsuit alleging false statements about failed Phase 3 trials ORBIT and COSMIC. Investors from June 2023-December 2025 eligible; lead plaintiff deadline April 2026.
MREOsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Mereo BioPharma Faces Securities Lawsuit Over Failed Drug Trial Disclosures

Rosen Law Firm urges MREO investors to join class action over alleged misleading statements regarding setrusumab Phase 3 trial failures.
MREOinvestor lossessecurities class action
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Mereo BioPharma Faces Securities Litigation Over Clinical Trial Disclosures

Mereo BioPharma faces securities litigation alleging it misled investors about Phase 3 clinical trial results for setrusumab, failing to disclose the trials missed primary endpoints.
MREOsecurities class actionmisleading statements